ClinicalTrials.gg
CompletedNCT04638439Updated Jun 10, 2026

The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

A Phase 1 interventional study of P1101 + Nivolumab + Entecavir in Chronic Hepatitis B Infection and Chronic Hepatitis D Infection, sponsored by PharmaEssentia. Completed at 5 sites in Taiwan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by PharmaEssentia · Phase 1, Interventional, and Treatment

How we know · 8 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Hepatitis B, Chronic with a site in Taiwan — 3 open to participants now, 10 under way, 1 of them phase 3. Hepatitis B, Chronic · Taiwan.

Enrollment
80th of 88
20 · median 120
Started
2022
with 7 others
Phase 1
15 of 99
none open now
Registered
73rd of 99
by date

Among the 99 studies in Hepatitis B, Chronic with a site in Taiwan, this one is the 80th largest by enrollment of the 88 interventional ones that give a count, is one of 8 that started in 2022, is one of 15 in phase 1, and was the 73rd registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 99 studies in Hepatitis B, Chronic with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Hepatitis B, Chronic with a site in Taiwan, or all of them as a file.
02

Study summary

Primary objective:

To evaluate the safety and tolerability of sequential administration of P1101 and anti-PD1 in patient with chronic hepatitis B or D infection

Secondary objectives:

  1. To explore HBsAg loss and kinetics during the study period
  2. To assess the anti-viral effect during the study period
  3. To evaluate the rate of ALT normalization
Read the detailed description

There are 20 scheduled visits (screening, treatment weeks \& follow-up weeks) for patients which include screening visit, TW0 (baseline), TW2, TW4, TW6, TW8, TW10, TW12, TW13, TW15, TW17, TW19, TW21, TW23 (EOT), FW4, FW8, FW12, FW16, FW20 and FW24.

03

Conditions studied

  • Chronic Hepatitis B Infection
  • Chronic Hepatitis D Infection

Browse trials for

Keywords

  • P1101
  • Anti-PD1
  • HBV
  • HDV
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Positive for for at least 6 months, either HBeAg (+) or HBeAg (-), and ≤ 10X at screening;
  2. Interferon naïve;
  3. Quantitative HBsAg Level \< 5,000 IU/mL at screening; HBV DNA \< 2,000 IU/mL (patients are either under NUC treatment or not);
  4. Adults ≥20 years of age; patients who are over 70 years of age must be in generally good health depending upon the Investigator's judgment;
  5. Laboratory test results before study entry: WBC ≥ 3,000/mm3; ≥ 1,500/mm3; ≥ 90,000/mm3; ≥ 10g/dL; e- ≥ 60mL/min;
  6. without abnormalities before study entry;
  7. Be able to attend all scheduled visits and to comply with all study procedures;
  8. Patients with anti-HDV (+) can be enrolled;
  9. Patients with fibrosis stage \< F3 can be enrolled;
  10. Willing to provide written ;

Exclusion criteria

Exclusion Criteria:

  1. illness or surgery that might interfere with study participation;
  2. Clinically significant vital sign abnormalities or fever [body temperature >38℃]);
  3. History of significant alcohol or drug abuse within 6 months prior to the screening visit (alcohol consumption of more than 14 units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or refusal to abstain from alcohol or illicit drugs throughout the study;
  4. Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bi-polar disorder, schizophrenia, suicidal ideation or history of suicidal attempt), neurological, cardiovascular (i.e. uncontrolled hypertension, congestive heart failure (≥ class 2), serious cardiac arrhythmia, significant coronary artery stenosis, unstable angina) or recent stroke or myocardial infarction), pulmonary, hematologic, immunologic, diseases, thyroid or other endocrine diseases, metabolic (e.g. diabetes mellitus with > 8.0%) or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias;
  5. Pregnant patient, female patient or the spouse of male patient, with who is unwilling or unable to practice adequate , defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices throughout the study;
  6. History of severe allergic or reactions, e.g. hypersensitivity to the active substance or to any of the of Ropeginterferon alfa-2b (P1101), bronchospasm, angioedema, asthma, or anaphylaxis;
  7. Therapy with any systemic anti-viral treatment, anti-neoplastic, or immunomodulatory treatment (including supraphysiologic doses of and radiation) within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug;
  8. A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis;
  9. Body organ transplant or taking ;
  10. Use drug of other clinical trials within 4 weeks prior to the first dose of the study drug;
  11. History of diagnosed or treated within 5 years prior to screening (except for localized treatment of squamous or non-invasive basal cell skin cancers; cervical carcinoma in situ);
  12. History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia);
  13. Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within 3 months prior to screening;
  14. Clinically significant medical conditions known to interfere absorption, distribution, metabolism or excretion of the study drugs;
  15. Decompensated liver disease, which includes but not limited to the following: total ≥2 mg/dL (except in Gilbert syndrome), direct bilirubin ≥2X , albumin level \< 3.5 g/dL, ≥1.5; clinical evidence of ascites, liver decompensation, hepatic encephalopathy, oesophageal varices or cirrhosis as identified by ultrasound or any other examination before study entry;
  16. Significant steatohepatitis by ultrasound or other examination at the discretion of investigator;
  17. Other form of significant chronic liver diseases, except those mentioned above (e.g. , HDV);
  18. Significant or major fundoscopic findings at screening including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilledema, optic atrophy, microaneurysms and macular changes;
  19. Positive for anti- or anti-;
  20. Prior therapy with , anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathway;
  21. Any to receiving anti-PD-1 antibody (e.g. active or a history of life-threatening autoimmune conditions, corticosteroids treatment required) or hypersensitivity to the constituents of anti-PD-1 antibody;
  22. Patients under monotherapy by telbivudine or any other combination therapy with telbivudine.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    P1101 + Nivolumab + Entecavir

    Drug: P1101 + Nivolumab + Entecavir

Interventions

06

What researchers measure

Primary outcomes

  1. Safety: AE/SAE

    Number of patients with adverse events, including SAEs

    Time frame: Through study Follow-up Week 24 (up to 330 days)

  2. Safety: clinically significant abnormalities

    Number of patients with clinically significant abnormalities, including vital sign, physical examination, electrocardiogram (ECG) and laboratory data

    Time frame: Through study Follow-up Week 24 (up to 330 days)

Secondary outcomes

  1. Subjects with HBsAg loss

    The percentage of subjects with HBsAg loss at treatment week 12, 23 and follow up week 12, 24 in the treatment group

    Time frame: Treatment Week 12, Treatment Week 23, Follow-up Week 12 and Follow-up Week 24

  2. Subjects with HBsAg reduction from baseline

    The percentage of subjects with HBsAg reduction from baseline at treatment week 12, 23 and follow up week 12, 24 in the treatment group

    Time frame: Treatment Week 12, Treatment Week 23, Follow-up Week 12 and Follow-up Week 24

  3. Subjects with HBsAg seroconversion

    The percentage of subjects with HBsAg seroconversion at treatment week 12, 23 and follow up week 12, 24 in the treatment group

    Time frame: Treatment Week 12, Treatment Week 23, Follow-up Week 12 and Follow-up Week 24

  4. Subjects with undetectable HBV DNA

    The percentage of subjects with undetectable HBV DNA at treatment week 12, 23 and follow up week 12, 24 in the treatment group

    Time frame: Treatment Week 12, Treatment Week 23, Follow-up Week 12 and Follow-up Week 24

  5. Subjects with ≥ 2 log10 decline from baseline in HDV RNA

    The percentage of subjects with ≥ 2 log10 decline from baseline in HDV RNA at treatment week 12, 23 and follow up week 12, 24 in the treatment group

    Time frame: Treatment Week 12, Treatment Week 23, Follow-up Week 12 and Follow-up Week 24

  6. Subjects with undetectable HDV RNA

    The percentage of subjects with undetectable HDV RNA at treatment week 12, 23 and follow up week 12, 24 in the treatment group

    Time frame: Treatment Week 12, Treatment Week 23, Follow-up Week 12 and Follow-up Week 24

  7. Subjects with ALT normalization

    The percentage of subjects with ALT normalization at treatment week 12, 23 and follow up week 12, 24 in the treatment group

    Time frame: Treatment Week 12, Treatment Week 23, Follow-up Week 12 and Follow-up Week 24

07

Study locations

5 sites
  • Chia-Yi Christian Hospital
    Chiayi City, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Taipei Medical University Hospital
    Taipei, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
  • Chang Gung Memorial Hospital, Linkou
    Taoyuan City, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Apr 2026, 43 months.

Of 74 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 43 months is above that.

Counting every sponsor, half of 82 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 20, 2020
StartActual
Aug 17, 2022
Primary completionActual
Apr 8, 2026
CompletionActual
Apr 8, 2026
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04638439
Lead sponsor
PharmaEssentia
Responsible party
Sponsor
First posted
Nov 20, 2020
Start date
Aug 17, 2022
Primary completion
Apr 8, 2026
Completion
Apr 8, 2026
Last update
Jun 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ropeginterferon alfa-2b · Nivolumab · Entecavir

Start the discussion